1. Development of an EGFR-targeting toxin with optimal biological activity, purity and construct size to facilitate tumor delivery with PCI.
  2. Evaluation of clinically relevant adjuvants to PCI-delivered targeted toxins.
  3. PCI-based targeted therapy for treatment of resistant sarcoma
  4. Mechanistic insight into the in vivo efficacy of targeted toxins delivered by PCI


Page visits: 714